Document:

EX-10.16

 Exhibit 10.16 

INTRA-CELLULAR THERAPIES, INC. 

EMPLOYEE PROPRIETARY INFORMATION, 

INVENTIONS, AND NON-COMPETITION AGREEMENT 

In consideration of my employment or continued employment by INTRA-CELLULAR THERAPIES,
INC. (the “Company”), and the compensation now and hereafter paid to me, I hereby agree as follows: 
  

	 	1.	 NONDISCLOSURE. 

1.1    Recognition of Company’s Rights; Nondisclosure. At all times during my employment
and thereafter, I will hold in strictest confidence and will not disclose, use, lecture upon or publish any of the Company’s Proprietary Information (defined below), except as such disclosure, use or publication may be required in connection
with my work for the Company, or unless an officer of the Company expressly authorizes such in writing. I will obtain Company’s written approval before publishing or submitting for publication any material (written, verbal, or otherwise) that
relates to my work at Company and/or incorporates any Proprietary Information. I hereby assign to the Company any rights I may have or acquire in such Proprietary Information and recognize that all Proprietary Information shall be the sole property
of the Company and its assigns. I have been informed and acknowledge that the unauthorized taking of the Company’s trade secrets may subject me to civil and/or criminal penalties. 

1.2    Proprietary Information. The term “Proprietary Information” shall
mean any and all confidential and/or proprietary knowledge, data or information of the Company. By way of illustration but not limitation, “Proprietary Information” includes (a) tangible and intangible information relating to
antibodies and other biological materials, cell lines, samples of assay components, media and/or cell lines and procedures and formulations for producing any such assay components, media and/or cell lines, formulations, products, processes, know-how, designs, formulas, methods, developmental or experimental work, clinical data, improvements, discoveries, plans for research, new products (“Inventions”); (b) marketing and selling,
business plans, budgets and unpublished financial statements, licenses, prices and costs, suppliers and customers; and (c) information regarding the skills and compensation of other employees of the Company. Notwithstanding the foregoing, it is
understood that, at all such times, I am free to use information which is generally known in the trade or industry, which is not gained as result of a breach of this Agreement, and my own, skill, knowledge,
know-how and experience to whatever extent and in whichever way I wish. 

1.3    Third Party Information. I understand, in addition, that the Company has received and
in the future will receive from third parties confidential or proprietary information (“Third Party Information”) subject to a duty on the Company’s part to maintain the confidentiality of such information and to use it only
for certain limited purposes. During the term of my employment and thereafter, I will hold Third Party Information in the strictest confidence and will not disclose to anyone (other than Company personnel who need to know such information in
connection with their work for the Company) or use, except in connection with my work for the Company, Third Party Information unless expressly authorized by an officer of the Company in writing. 

 1.4    No Improper Use of Information of Prior
Employers and Others. During my employment by the Company I will not improperly use or disclose any confidential information or trade secrets, if any, of any former employer or any other person to whom I have an obligation of confidentiality,
and I will not bring onto the premises of the Company any unpublished documents or any property belonging to any former employer or any other person to whom I have an obligation of confidentiality unless consented to in writing by that former
employer or person. I will use in the performance of my duties only information which is generally known and used by persons with training and experience comparable to my own, which is common knowledge in the industry or otherwise legally in the
public domain, or which is otherwise provided or developed by the Company. 
  

	 	2.	 ASSIGNMENT OF INVENTIONS. 

2.1    Proprietary Rights. The term “Proprietary Rights” shall mean all
trade secret, patent, copyright, mask work and other intellectual property rights or “moral rights” throughout the world. “Moral rights” refers to any rights to claim authorship of an Invention or to object to or prevent the
modification of any Invention, or to withdraw from circulation or control the publication or distribution of any Invention, and any similar right, existing under judicial or statutory law of any country in the world, or under any treaty, regardless
of whether or not such right is denominated or generally referred to as a “moral right.” 

2.2    Prior Inventions. Inventions, if any, patented or unpatented, which I made prior to
the commencement of my employment with the Company are excluded from the scope of this Agreement. To preclude any possible uncertainty, I have set forth on Exhibit A (Previous Inventions) attached hereto a complete list of
all Inventions that I have, alone or jointly with others, conceived, developed or reduced to practice or caused to be conceived, developed or reduced to practice prior to the commencement of my employment with the Company, that I consider to be my
property or the property of third parties and that I wish to have excluded from the scope of this Agreement (collectively referred to as “Prior Inventions”). If disclosure of any such Prior Invention would cause me to violate any
prior confidentiality agreement, I understand that I am not to list such Prior Inventions in Exhibit A but am only to disclose a cursory name for each such invention, a listing of the party(ies) to whom it belongs and the
fact that full disclosure as to such inventions has not been made for that reason. A space is provided on Exhibit A for such purpose. If no such disclosure is attached, I represent that there are no Prior Inventions. If, in the course of my
employment with the Company, I incorporate a Prior Invention into a Company product, process or machine, the Company is hereby granted and shall have a nonexclusive, royalty-free, irrevocable, perpetual, worldwide license (with rights to sublicense
through multiple tiers of sublicensees) to make, have made, modify, use and sell such Prior Invention. Notwithstanding the foregoing, I agree that I will not incorporate, or permit to be incorporated, Prior Inventions in any Company Inventions
without the Company’s prior written consent. 
 2.3    Assignment of Inventions.
Subject to Sections 2.4, and 2.6, I hereby assign and agree to assign in the future (when any such Inventions or Proprietary Rights are first reduced to practice or first fixed in a tangible medium, as applicable) to the Company all my right, title
and interest in and to any and all Inventions (and all Proprietary Rights with respect thereto) whether or not patentable or registrable under copyright or similar statutes, made or conceived or reduced to practice or learned by me, either alone or
jointly with others, during the period of my employment with the Company. Inventions assigned to the Company, or to a third party as directed by the Company pursuant to this Section 2, are hereinafter referred to as “Company
Inventions.” 

 2.4    Unassigned Inventions. I recognize
that this Agreement will not be deemed to require assignment of any Invention that was developed entirely on my own time without using the Company’s equipment, supplies, facilities, or trade secrets and neither related to the Company’s
actual or anticipated business, research or development, nor resulted from work performed by me for the Company. 

2.5    Obligation to Keep Company Informed. During the period of my employment and for six
(6) months after termination of my employment with the Company, I will promptly disclose to the Company fully and in writing all Inventions authored, conceived or reduced to practice by me, either alone or jointly with others. In addition, I
will promptly disclose to the Company all patent applications filed by me or on my behalf within a year after termination of employment. The Company will keep in confidence and will not use for any purpose or disclose to third parties without my
consent any confidential information disclosed in writing to the Company pursuant to this Agreement. 

2.6    Government or Third Party. I also agree to assign all my right, title and interest in
and to any particular Company Invention to a third party, including without limitation the United States, as directed by the Company. 

2.7    Works for Hire. I acknowledge that all original works of authorship which are made by
me (solely or jointly with others) within the scope of my employment and which are protectable by copyright are “works made for hire,” pursuant to United States Copyright Act (17 U.S.C., Section 101). 

2.8    Enforcement of Proprietary Rights. I will assist the Company in every proper way to
obtain, and from time to time enforce, United States and foreign Proprietary Rights relating to Company Inventions in any and all countries. To that end I will execute, verify and deliver such documents and perform such other acts (including
appearances as a witness) as the Company may reasonably request for use in applying for, obtaining, perfecting, evidencing, sustaining and enforcing such Proprietary Rights and the assignment thereof. In addition, I will execute, verify and deliver
assignments of such Proprietary Rights to the Company or its designee. My obligation to assist the Company with respect to Proprietary Rights relating to such Company Inventions in any and all countries shall continue beyond the termination of my
employment, but the Company shall compensate me at a reasonable rate after my termination for the time actually spent by me at the Company’s request on such assistance. 

In the event the Company is unable for any reason, after reasonable effort, to secure my signature on any document needed in connection with the actions
specified in the preceding paragraph, I hereby irrevocably designate and appoint the Company and its duly authorized officers and agents as my agent and attorney in fact, which appointment is coupled with an interest, to act for and in my behalf to
execute, verify and file any such documents and to do all other lawfully permitted acts to further the purposes of the preceding paragraph with the same legal force and effect as if executed by me. I hereby waive and quitclaim to the Company any and
all claims, of any nature whatsoever, which I now or may hereafter have for infringement of any Proprietary Rights assigned hereunder to the Company. 
  

	 	3.	 RECORDS. I agree to keep and maintain adequate and current records (in the
form of notes, sketches, drawings and in any other form that may be required by the Company) of all Proprietary Information developed by me and all Inventions made by me during the period of my employment at the Company, which records shall be
available to and remain the sole property of the Company at all times. 

  

	 	4.	 DUTY OF LOYALTY DURING
EMPLOYMENT. I understand that my employment with the Company requires my full attention and effort. I agree that during the period of my employment by the Company I will not, without the Company’s express written consent,
engage in any employment or business activity other than for the Company, including but not limited to employment or business activity which is competitive with, or would otherwise conflict with, my employment by the Company. 

	 	5.	 NO SOLICITATION OF EMPLOYEES,
CONSULTANTS OR CONTRACTORS. I agree that for the period of my employment by the Company and for one (1) year after the date my employment by the Company ends for any reason, including but not
limited to voluntary termination by me or involuntary termination by the Company, I will not, either directly or through others, (i) solicit or attempt to solicit any employee of the Company to end his or her relationship with the Company; and
(ii) solicit any consultant or contractor of the Company, with whom I had contact or whose identity I learned as a result of my employment with the Company to diminish or materially alter its relationship with the Company.

  

	 	6.	 NON-COMPETE
PROVISION. I agree that for the period of my employment with the Company, and for the period of one (1) year after the date my employment ends for any reason, including but not limited to voluntary termination by me or
involuntary termination by the Company, I will not provide services, similar to those I provided to the Company, to any person or entity in competition (as defined below) with the Company. I acknowledge that this
non-compete provision is limited to the types of activities and services I provided in my employment with the Company. 

At the present time, the Company engages in the research and discovery and commercialization of treatments for schizophrenia, bi-polar depression, behavior disturbances in dementia, Parkinson’s disease, heart failure, substance use disorder and pain, and therefore entities and individuals which provide similar products or
services are defined as in competition with the Company. The parties understand that the scope and nature of my activities and services, and the Company’s business, products or services, may change as the Company develops. The parties agree
that the scope of this provision will change to cover any changes in my activities or services, as well as any changes in the Company’s business, products or services, during my employment. 

 

	 	7.	 NO CONFLICTING AGREEMENT OR
OBLIGATION. I represent that my performance of all the terms of this Agreement and as an employee of the Company does not and will not breach any agreement or obligation of any kind made prior to my employment by the Company,
including agreements or obligations I may have with prior employers or entities for which I have provided services. I have not entered into, and I agree I will not enter into, any agreement or obligation either written or oral in conflict herewith.

  

	 	8.	 RETURN OF COMPANY DOCUMENTS. When I
leave the employ of the Company, I will deliver to the Company any and all drawings, notes, memoranda, specifications, devices, formulas, and documents, together with all copies thereof, and any other material containing or disclosing any Company
Inventions, Third Party Information or Proprietary Information of the Company. I further agree that any property situated on the Company’s premises and owned by the Company, including disks and other storage media, filing cabinets or other work
areas, is subject to inspection by Company personnel at any time with or without notice. Prior to leaving, I will cooperate with the Company in completing and signing the Company’s termination statement. 

 

	 	9.	 LEGAL AND EQUITABLE REMEDIES. I
recognize that in the course of employment with the Company, I will have access to Proprietary Information, to Third Party Information, and to employees, consultants, contractors, clients, and customers of the Company. I also recognize that the
services I will be employed to provide are personal and unique. I understand that because of this the Company may sustain irreparable injury if I violate this Agreement. In order to limit or prevent such irreparable injury, the Company shall have
the right to enforce this Agreement and any of its provisions by injunction, specific performance or other equitable relief, without bond and without prejudice to any other rights and remedies that the Company may have for a breach of this
Agreement. 

  

	 	10.	 NOTICES. Any notices required or permitted hereunder shall be given to the
appropriate party at the address specified below or at such other address as the party shall specify in writing. Such notice shall be deemed given upon personal delivery to the appropriate address or if sent by certified or registered mail, three
(3) days after the date of mailing. 

	 	11.	 NOTIFICATION OF NEW EMPLOYER. In the
event that I leave the employ of the Company, I authorize the Company to provide notice of my rights and obligations under this Agreement to my subsequent employer and to any other entity or person to whom I provide services. 

 

	 	12.	 GENERAL PROVISIONS. 

12.1    Governing Law; Consent to Personal Jurisdiction. This Agreement will be governed by
and construed according to the laws of the State of New York, as such laws are applied to agreements entered into and to be performed entirely within New York between New York residents. I hereby expressly consent to the personal jurisdiction of the
state and federal courts for New York County, New York in any lawsuit filed there against me by Company arising from or related to this Agreement. 

12.2    Severability. In case any one or more of the provisions, subsections, or sentences
contained in this Agreement shall, for any reason, be held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect the other provisions of this Agreement, and this Agreement shall be
construed as if such invalid, illegal or unenforceable provision had never been contained herein. Moreover, if any one or more of the provisions contained in this Agreement shall for any reason be held to be excessively broad as to duration,
geographical scope, activity or subject, it shall be construed by limiting and reducing it, so as to be enforceable to the extent compatible with the applicable law as it shall then appear. 

12.3    Successors and Assigns. This Agreement will be binding upon my heirs, executors,
administrators and other legal representatives and will be for the benefit of the Company, its successors, and its assigns. 

12.4    Survival. The provisions of this Agreement shall survive the termination of my
employment and the assignment of this Agreement by the Company to any successor in interest or other assignee. 

12.5    Employment At-Will. I agree and understand
that I am employed at-will, and that nothing in this Agreement shall change this at-will status or confer any right with respect to continuation of employment by the
Company, nor shall it interfere in any way with my right or the Company’s right to terminate my employment at any time, with or without cause. 

12.6    Waiver. No waiver by the Company of any breach of this Agreement shall be a waiver of
any preceding or succeeding breach. No waiver by the Company of any right under this Agreement shall be construed as a waiver of any other right. The Company shall not be required to give notice to enforce strict adherence to all terms of this
Agreement. 
 12.7    Entire Agreement. The obligations pursuant to Sections 1 and 2 of
this Agreement shall apply to any time during which I was previously employed, or am in the future employed, by the Company as a consultant if no other agreement governs nondisclosure and assignment of inventions during such period. This Agreement
is the final, complete and exclusive agreement of the parties with respect to the subject matter hereof and supersedes and merges all prior discussions between us. No modification of or amendment to this Agreement, nor any waiver of any rights under
this Agreement, will be effective unless in writing and signed by the party to be charged. Any subsequent change or changes in my duties, salary or compensation will not affect the validity or scope of this Agreement. 

This Agreement shall be effective as of the first day of my employment with the Company, namely:
            , 201    . 

 I HAVE READ THIS AGREEMENT
CAREFULLY AND UNDERSTAND ITS TERMS. I HAVE COMPLETELY FILLED OUT EXHIBIT A TO
THIS AGREEMENT. 
  

	
	 Dated: December 10, 2018

	
	 /s/ Mark Neumann

	 (Signature)

 

	
	Mark Neumann
	(Printed Name)

 ACCEPTED AND
AGREED TO: 
 INTRA-CELLULAR THERAPIES, INC. 

			
		
	By:	 	 /s/Lawrence Hineline

			
		
	Title:	 	 Chief Financial Officer

			
	
	430 E. 29th St. New York NY 10016
	(Address)

			
	
	    
	
	 Dated:  December 14, 2018Exhibit 1014 for Q4 2018

		

			Exhibit 10.14

		

		

			 

		

		
			MURPHY OIL CORPORATION
		

		
			﻿
		

		
			PERFORMANCE-BASED RESTRICTED STOCK UNIT – STOCK SETTLED
		

		
			GRANT AGREEMENT
		

		
			﻿
		

			
					
						 

					
					
						 

					
					
						 

				
	
					
						Performance-Based

					
						Restricted Stock Unit Award Number

					
					
						Name of Grantee

					
						 

					
						 

					
					
						Number of Restricted Stock Units Subject to this Grant

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						[[GRANTNUMBER]]

					
					
						[[NAME]]

					
					
						[[UNITSGRANTED]]

				
	
					
						 

					
					
						 

					
					
						 

				

		
			﻿
		

		
			This Performance-Based Restricted Stock Unit Award (this  “Award”) is granted on and dated [•] (the “Grant Date”), by Murphy Oil Corporation, a Delaware corporation (the “Company”), pursuant to and for the purposes of the 2018 Long-Term Incentive Plan (the “Plan”).  Any terms used herein and not otherwise defined shall have the meanings set forth in the Plan.
		

		
			﻿
		

		
			This Agreement is subject to the following terms and provisions. In addition, certain terms and provisions applicable to this Award will be communicated to you in a separate brochure (the “Brochure”). By accepting this Agreement, you agree to the terms and provisions set forth below, in the Plan and in the Brochure. 
		

		
			﻿
		

		
			1.   The Company hereby grants to the employee named above (the “Grantee”) a Performance-Based Award of Restricted Stock Units each equal in value to one share of Common Stock.
		

		
			﻿
		

		
			2.   This Award is subject to the following vesting and time lapse restrictions:
		

		
			(a)  In the event that the Performance Measures as set forth in Section 3 below are satisfied in accordance with the Plan, the size of this Award will be determined by the Committee, and the Grantee will be paid the value of his or her units in Shares during the first quarter of the fiscal year immediately following the completion of the three-year performance measurement period;  provided that, except as set forth in Sections 2(c) and 2(d) below, the Grantee is employed by the Company on both the last day of the performance measurement period and the date that the Committee determines the size of this Award.  
		

		
			(b)  In the event that the Grantee’s employment terminates any time prior to the date that the Committee determines the size of this Award, except as set forth in Sections 2(c) and 2(d) below, he or she will forfeit all units pursuant to this Award.
		

		
			(c)  In the event of the Grantee’s death, disability, or retirement (as determined in accordance with the Plan), the Grantee will receive the pro-rata number of units earned for performance completed based upon the number of months worked pursuant to this Award up to the time of the death, disability, or retirement event.  In the event that the Performance Measures are satisfied in accordance with the Plan and, as set forth in Section 3 below, the size of this Award is determined by the Committee, the Grantee will be paid his or her  Shares during the first quarter of the fiscal year immediately following the completion of the three-year performance measurement period. 
		

		
			(d)  If the Grantee is not an employee of the Company who is the Chief Executive Officer (“CEO’), who reports directly to the CEO, or is a Named Executive Officer of the Company at any time during the period beginning on the grant date of this Award and ending on the date on which a Change in Control occurs, this Award will fully vest and one hundred percent (100%) of the performance-based restricted stock units granted will be deemed to be earned at the target level of performance and will be paid in full, without restrictions, upon such Change in Control;  provided,  however, that no payment will be made until the first quarter of 2022 unless such Change in Control also qualifies as a “change in control event” as determined under Section 409A.  
		

		

		

		 

		

			 

		

 

		

			 

		

		
		

		
			(e)  If the Grantee is an employee of the Company who is the Chief Executive Officer (“CEO’), who reports directly to the CEO, or is a Named Executive Officer at any time during the period beginning on the grant date of this Award and ending on the date on which a Change in Control occurs, this Award will fully vest and one hundred percent (100%) of the performance-based restricted stock units granted will be deemed to be earned at the target level of performance and will be paid in full, without restrictions, upon the occurrence of a Qualifying Termination of Employment.  “Qualifying Termination of Employment” means the termination of the Grantee’s employment within the two-year period immediately following a Change in Control (x) by the Company or any of its affiliates without Cause or (y) by the Grantee for Good Reason.  Upon a Qualifying Termination of Employment, payment will be made as soon as reasonably practicable following the date of the Qualifying Termination of Employment, less any Shares or amounts deducted for applicable withholding taxes.
		

		
			(f)  For purposes of this Agreement, “Cause” means the occurrence of any of the following:
		

		
			(i) Any act or omission by the Grantee which constitutes a material willful breach of the Grantee’s obligations to the Company or any of its affiliates or the Grantee’s continued and willful refusal to substantially perform satisfactorily any duties reasonably required of the Grantee, which results in material injury to the interest or business reputation of the Company or any of its affiliates and which breach, failure or refusal (if susceptible to cure) is not corrected (other than failure to correct by reason of the Grantee’s incapacity due to physical or mental illness) within thirty (30) days after written notification thereof to the Grantee by the Company; provided that no act or failure to act on the Grantee’s part shall be deemed willful unless done or omitted to be done by the Grantee not in good faith and without reasonable belief that the Grantee’s action or omission was in the best interest of the Company or its affiliates;
		

		
			(ii) The Grantee’s commission of any dishonest or fraudulent act, which has caused or may reasonably be expected to cause a material injury to the interest or business reputation of the Company or any of its affiliates;
		

		
			(iii) The Grantee’s plea of guilty or nolo contendere to or conviction of a felony under the laws of the United States or any state thereof or any other plea or confession of a similar crime in a jurisdiction in which the Company or any of its affiliates conducts business; or
		

		
			(iv) The Grantee’s commission of a fraudulent act or participation in misconduct which leads to a material restatement of the Company’s financial statements.
		

		
			(g)  For purposes of this Agreement, “Good Reason” means the occurrence of any of the following:
		

		
			(i) Any material diminution in the Grantee’s title, status, position, the scope of duties assigned, responsibilities or authority, including the assignment to the Grantee of any duties, responsibilities or authority in any manner adverse to the Grantee or inconsistent with the duties, responsibilities and authority assigned to the Grantee prior to a Change in Control;
		

		
			(ii) Any reduction in the Grantee’s base salary, annual target cash bonus opportunity or long-term incentive award opportunity immediately prior to a Change in Control;
		

		

		

		 

		

			 

		

 

		

			 

		

		(iii) A relocation of more than fifty  (50) miles from the location of the Grantee’s principal job location or office prior to a Change in Control; or
		

		
			(iv) Any other action or inaction that constitutes a material breach by the Company or any of its affiliates of any employment or similar agreement pursuant to which the Grantee provides services to the Company or any of its affiliates;
		

		
			provided, that the Grantee provides the Company with a written notice of termination indicating the Grantee’s intent to terminate his or her employment for Good Reason within ninety (90) days after the Grantee becoming aware of any circumstances set forth above, that the Grantee provides the Company with at least thirty (30) days following receipt of such notice to remedy such circumstances, and, if the Company fails to remedy such circumstances during such thirty (30) day period, that the Grantee terminates his or her employment no later than sixty (60) days after the end of such thirty (30) day period.
		

		
			3.   The Performance Measure for this Award is the Company’s total shareholder return (“TSR”) over the three-year performance measurement period compared to the TSR of the Company’s peer group.  The amount of this Award earned (the “Payout Percentage”) is based on the Company’s percentile ranking in TSR over the three-year performance measurement period compared to that of the peer group.  The Payout Percentage will be interpolated for points between the 25th and 90th percentiles.    
		

		
			﻿
		

			
					
						 

				
	
					
						Percentile Rank

					
					
						Payout Percentage

				
	
					
						Below 25th Percentile

					
					
						0.0%

				
	
					
						25th Percentile

					
					
						50.0%

				
	
					
						50th Percentile

					
					
						100.0%

				
	
					
						75th Percentile

					
					
						125.0%

				
	
					
						At or Above 90th Percentile

					
					
						150.0%

				

		
			﻿
		

		
			Notwithstanding the foregoing, if the Company’s TSR over the three-year performance measurement period is less than 0%, the Payout Percentage shall not exceed 100%. 
		

		
			﻿
		

		
			4.   Provided that the Performance Measures as set forth in Section 3 above are satisfied and Shares are to be paid to the Grantee without restriction, such Shares paid will be the net Shares earned pursuant to Section 3 above less the number of Shares which must be withheld to satisfy the tax withholding requirements applicable to such payment of Shares.
		

		
			﻿
		

		
			5.   In the event of any relevant change in the capitalization of the Company prior to the issuance of Shares underlying the units, the number of units may be equitably adjusted pursuant to the Plan to reflect that change.
		

		
			﻿
		

		
			6.   This Award is not assignable except as provided under the Plan in the case of death and is not subject in whole or in part to attachment, execution, or levy of any kind.
		

		
			﻿
		

		
			7.   The Grantee shall have no voting rights with respect to Shares underlying the units unless and until such Shares are reflected as issued and outstanding shares on the Company’s stock ledger.
		

		
			﻿
		

		
			8.   The Grantee is eligible to receive a payment equivalent to the dividends paid on shares of Common Stock equal in number to the Restricted Stock Units granted hereunder.  These dividend equivalents will be accrued over the performance period and included in any Shares issued at the end of the period.  In the event that Shares are not earned, the accompanying accrued dividend equivalents will be forfeited.
		

		
			﻿
		

		
			9.   The Plan, this Agreement and the Brochure are administered by the Committee.  The Committee has the full authority and discretion to interpret and administer the Plan consistent with the terms and provisions of the Plan.
		

		
			﻿
		

			
					
						﻿

					
					
						 

					
					
						 

				
	
					
						Attest:

					
					
						Murphy Oil Corporation

				
	
					
						﻿

					
					
						 

					
					
						 

				
	
					
						﻿

					
					
						By 

					
					
						 

				

		
			﻿

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00292-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00292-of-00352.parquet"}]]